Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics (CORT) – Form 4 filing, 08/05/2025: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,823 employee stock options at an exercise price of $13.56 (cost ≈ $79k) and immediately sold the same 5,823 shares under a pre-arranged 10b5-1 plan at a weighted-average $67.5129, generating gross proceeds of ≈ $393k and a spread of ≈ $314k before taxes.
Following the transactions Lyon directly owns 10,066 CORT common shares, including 1,552 unvested RSAs that vest one year from their respective grant dates, and retains 31,571 vested options. No other classes of securities were affected. The transaction neither alters total shares outstanding nor signals corporate fundamentals, but it represents a partial monetisation by a senior officer at ~5× the option strike.
Corcept Therapeutics Inc. (CORT) filed a Form 144 indicating that William Guyer intends to sell up to 20,000 common shares through broker Stifel Nicolaus on or about 08/05/2025. The shares have an estimated aggregate market value of $1.44 million, based on recent market prices. Corcept has 106.04 million shares outstanding, so the planned sale represents roughly 0.02% of total shares.
The filing also discloses that Guyer has already sold 64,301 shares in the past three months, generating $4.73 million in gross proceeds across six transactions. The forthcoming sale continues this selling trend but remains immaterial in size relative to total float. No pricing, earnings, or operational data are provided in the notice, and the signer affirms no undisclosed adverse information.
Corcept Therapeutics Inc. (CORT) – Form 144 filing discloses a proposed sale of 5,000 common shares by shareholder Joseph D. Lyon. The shares will be routed through Stifel Nicolaus & Co. on the NASDAQ with an estimated aggregate market value of $335,850 (based on the indicated $67.17 reference price). The company has 106.04 million shares outstanding, so the planned sale represents roughly 0.005 % of total shares.
The filer reports additional sales over the past three months totaling 18,527 shares for gross proceeds of $1.37 million. When combined with the proposed sale, Lyon’s total disposition for the rolling three-month window would reach 23,527 shares (~0.022 % of shares outstanding).
No purchase price was deferred; the 5,000 shares were acquired via stock-option exercise on 08/01/2025 and will be sold for cash. The filing contains the standard representation that the seller is unaware of undisclosed material adverse information and does not reference a Rule 10b5-1 plan.
Given the small size relative to the public float and absence of additional corporate disclosures, the filing appears routine and is unlikely to have a material impact on CORT’s valuation or trading dynamics.
Corcept Therapeutics (CORT) – Form 144 filing. President Sean Maduck has filed to sell 20,000 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. At the 07/31/25 reference price, the sale is valued at $1.34 million. The shares were just acquired the same day via stock-option exercise; therefore the transaction is likely part of routine option monetisation.
Maduck has already disposed of 64,403 shares during the past three months for ~$4.79 million in gross proceeds. After the proposed trade, cumulative sales disclosed in the filing period reach ~84 k shares. CORT has 106.04 million shares outstanding, making the new sale ~0.02 % of outstanding stock and therefore not materially dilutive. No earnings, guidance or operational data are provided; this notice is strictly an insider-sale disclosure.
Corcept Therapeutics (CORT) – Form 4 insider activity
Sean Maduck, President of Corcept Endocrinology, exercised low-priced options and immediately sold the underlying shares pursuant to a 10b5-1 plan:
- 17 Jul 2025: Exercised 4,315 options at $5.05; sold 4,315 shares at a weighted-avg $73.4771.
- 18 Jul 2025: Exercised 473 options at $5.05; sold 473 shares at $73.4404.
Total shares sold: 4,788; gross proceeds ≈ $351k; per-share spread ≈ $68.4.
Post-trade holdings: 17,705 shares direct; 99,693 shares indirect (89,693 trust + 10,000 LLC); 56,993 vested options; 1,877 unvested RSAs.
The divestiture equals ~4 % of Maduck’s reported equity exposure and was pre-scheduled, suggesting limited informational content for the broader CORT investment thesis.